NBD AI Bulletin - Beijing Wantai Biological Pharmacy Enterprise Co Ltd (the Company, SH 603392, close price: 247.99 yuan) announced on November 22 that as at the disclosure of this bulletin, Mr. Li Yimin, chief engineer of the Company, held about 4.51 million shares without restriction on sale in the Company, representing 0.7424% of the Company's total equity. Mr. Li plans to reduce his holdings by 150,000 shares via centralized bidding within three months following 15 trading days from the date of this notice.

The 2020 annual report shows that Beijing Wantai Biological Pharmacy Enterprise Co Ltd's main business is in vitro diagnosis, vaccine, accounting for 62.51%, 36.77% of revenue, respectively.

Beijing Wantai Biological Pharmacy Enterprise Co Ltd's chairman and general manager is Qiu Zixin, male, 57, without permanent residence abroad, bachelor's degree, researcher.

(By Lan Suying)

Disclaimer: The content and data of this article are for reference only and do not constitute investment advice. Please verify before use. Any action you take upon the information on this website is at your own risk.